Overview

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Status:
Terminated
Trial end date:
2017-11-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of AGS67E in subjects with acute myeloid leukemia (AML) and determine a safe dose for future development. In addition, this study will assess the pharmacokinetics (PK), the immunogenicity, and the anti-leukemic activity of AGS67E.
Phase:
Phase 1
Details
Lead Sponsor:
Agensys, Inc.
Astellas Pharma Global Development, Inc.